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Sustaining the release of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner is a potentially powerful techno- 
logy. A new drug carrier-dialdehyde starch nanoparticle (DASNP) that can sustain the loading and release of 5-fluorouracil (5-Fu) 
antitumor drug is reported in this study. IR spectrophotometer and 1H NMR confirmed the formation of aldehyde groups, and scan 
electron microscope determinations showed that the dialdehyde starch nanoparticles obtained had an average diameter of 90 nm. 
5-Fu, the model drug, was conjugated into nanoparticles by aldehyde groups. These 5-Fu-binding nanoparticles significantly en-
hanced breast cancer cell (MCF-7) inhibition in vitro compared with free 5-Fu. After subcutaneous 0 injection in the breast tu-
mor-loaded rats, 5-Fu-DASNP exhibited remarkable tumor-inhibitory efficacy determined by measuring tumor weight in vivo. 
The tumor inhibition of 5-Fu-DASNP was 61%±6%, whereas that of free 5-Fu was only 42%±4%. Bcl-2/Bax immunohistochem-
istry studies indicated that 5-Fu-DASNP remarkably induced tumor tissue necrosis. These results demonstrated that the DASNP 
prepared in this work is a potentially effective drug carrier.  
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Dialdehyde starch (DAS), one of the most valuable forms of 
oxidized starch, is prepared by oxidation of starch with pe-
riodic acid, a selective oxidant that can cleave the C2–C3 
bond of the anhydroglucose units forming the dialdehyde 
groups [1]. Dialdehyde starch can react with some com-
pounds, such as hydrazine, acid, amine, and imine, through 
two aldehyde groups in each glucose residual [2]. Thus, it 
has found wide application in industrial and pharmaceutical 
fields [3–6]. Majority of DAS production is consumed by 
the paper industry as wet strength improver [7–9]. DAS also 
evokes considerable interest in the food industry because of 
its potential applications, especially as component of biode-
gradable plastics for packaging, superabsorbents, and traps 
for removing heavy metals from industrial wastes [10,11].  
In pharmaceutics, dialdehyde starch has been studied as a 
drug carrier, using its conjugation with isoniazid. The char-
acteristics of dialdehyde starch as a polymer, particularly 
molecular weight distribution, dissolution, and degradation 
behavior, have been investigated in vitro in detail [12,13]. 
Dialdehyde starch as nanoparticles have been prepared for 
use as drug carriers. The results show that dialdehyde starch 
nanoparticles (DASNP) can be used as antitumor drug car-
riers, and that they have no acute-cytotoxicity. Hence, they 
are potentially useful drug carriers [14].  
In this study, DASNP was conjugated with 5-Fu to form 
multiple nanoparticles of 5-Fu-DASNP. 5-Fu-DASNP was 
characterized in terms of size, IR spectrum, 1H NMR, and 
drug loading and release. The in vitro anti-cancer activity of 
5-Fu-DASNP was determined using an MCF-7 cell line 
with MTT assay. On the other hand, the in vivo antitumor 
activity was assessed through a single subcutaneous injec-
tion of the nanoparticle formulation into an animal tumor 
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model to observe the sustained release effect and to com-
pare it with that of the injection of untreated 5-Fu. H&E 
staining and Bcl-2/Bax immunohistochemistry studies of 
the slips of tumors were administered to evaluate the apop-
tosis of the tumor cells in the body. 
1  Materials and methods 
1.1  Materials 
5-Fu was obtained from Sigma (Missouri, USA). All cell 
culture plasticwares were purchased from Corning (NY, 
USA). The RPMI 1640 cell culture medium and phosphate 
buffered saline (PBS) were obtained from Gibco (Grand 
island, NY, USA).  
1.2  Synthesis of DASNP and 5-Fu-DASNP 
DASNP was prepared according to our previously pub-
lished paper [14]. Hydrolyzing starch was oxidized with 
sodium periodate (NaIO4) to obtain dialdehyde starch 
(DAS). DAS was cross-linked with POCl3 in water-in-oil 
micro-emulsion to obtain dialdehyde starch nanoparticles 
(DASNPs) under room temperature. The oxidation degree 
(OD) of the prepared DASNPs was 40%±5%, and the dia- 
meter was in the range of 80 to 100 nm, which were uni-
form in size and well dispersed. 
About 50 mg DASNP was suspended in 1 mL distilled 
water. The pH was adjusted from 3 to 5 using 1 mol/L of 
HCl. 5-Fu dissolved in DMSO was added to the aqueous 
solution. The mixed solution was incubated for 3 h under 
room temperature (about 25°C). The resultant product was 
separated with ethanol and freeze dried. The product was 
completely dissolved in hot water. UV spectrophotometer 
(UV1600, Beijing Rayleigh Analytical Instrument Corp., 
China) was used to check the 5-Fu content in the solution, 
and pure 5-Fu was used to construct a calibration curve.  
1.3  Characteristics of DASNP and 5-Fu-DASNP  
Solid samples of DASNP and 5-Fu-DASNP (~200 mg) were 
ground with potassium bromide and then compressed into a 
thin pellet using a Model B Carver Laboratory Press (Fred S. 
Carver Inc., NJ, USA). The samples were analyzed using an 
infrared spectrophotometer (WQF-410, RAYLEIGHTM, Bei-
jing Rayleigh Analytical Instrument Corp., China). The 1H 
NMR spectrum of 5-Fu-DASNP was verified using the Nu-
cleus Magnetic Resonance system (INOVA-400, VARIANTM, 
Varian Inc., USA). A scanning electron microscope (SEM) 
(JSM-5800, JEOL Corp., Japan) was used to check the ap-
pearance and diameters of DASNP and 5-Fu-DASNP. 
1.4  Drug release rate determination 
About 10 mg 5-Fu-DASNP was suspended in 5 mL PBS at 
pH 7.4. The solution was dialyzed against a 50 mL buffer of 
a different pH value under stirring at 100 r/min and 37°C. 
About 5 mL of the medium was removed at certain intervals 
and replaced with fresh buffer to maintain the total volume. 
The amount of 5-Fu in the dialyzed solution was analyzed 
using UV-spectroscopy (UV1600, Beijing Rayleigh Ana-
lytical Instrument Corp., China). DASNP (without drug) 
was used as the blank sample, and the calibration curve was 
constructed as above. 
1.5  In vitro cytotoxicity assay 
The cytotoxicity of 5-Fu, DASNP, 5-Fu/DASNP, and 5-Fu- 
DASN were determined by measuring the cell growth inhi-
bition of the nanoparticles using a micro-reader (MK3, 
Thermo Electron Corp., USA). In this standardized assay, 
opaque white 96-well microtiter tissue culture plates were 
seeded with MCF-7 cells at a density of 10000 cells per 
well in 100 μL RPMI 1640 complete medium containing 
10% fetal bovine serum [15]. The cells were acclimated for 
24 h. The medium was removed, and 100 μL of the fresh 
medium containing the test compounds was added. All 
compounds were initially solubilized in 100% DMSO up to 
a final DMSO concentration of 1.0% each. Each of the 
compound concentration was tested in triplicate. 
1.6  In vivo antitumor activity assay 
The antitumor activities against subcutaneously implanted 
solid tumor induced by human breast cancer cells in nude 
mice were evaluated for saline, DASNP, 5-Fu, and 5-Fu- 
DASNP. BALB/c female nude mice (6 weeks old) were 
divided into 4 different groups consisting of 6 mice in each 
group [15]. MCF-7 cells (2×106 cells in 0.1 mL PBS (pH 
7.4)) were subcutaneously transplanted along the flank of 
the mice on day 0. The peri-tumoral drug injection started 
on day 8 when the tumor diameter reached approximately 
220 mm3. The first group (control group) was injected with 
0.1 mL saline every other day over the following 10 d, 
whereas the second group was injected with DASNP (20 
mg/kg body weight) the same way. The rest of the groups of 
mice were injected with 20 mg/kg body weight of free 5-Fu 
(third group), and with 20 mg/kg body weight of 5-Fu- 
DASNP (fourth group). The drug was injected six times. 
The tumor diameters in the mice were monitored using a 
digital caliper. These diameters were used as index for the 
in vivo antitumor activity of the drug. When the experiment 
was concluded after injection on day 10, the mice were sac-
rificed, and the solid tumors were obtained and weighed. 
The inhibitory ratio of the tumor was calculated using the 
formula (1Wdrug /Wsaline) ×100%, where W is the weight. 
1.7  Immunohistochemistry assay 
Bcl-2 is an inhibiting apoptosis gene largely expressed in 
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active tumor cells, whereas Bax is an opposite gene that 
promotes apoptosis. Both expressions compete in the tumor 
tissue. Thus, the ratio of Bcl-2-to-Bax was used to evaluate 
the apoptosis of tumor cells [16,17]. Immunohistochemical 
methods were adopted in this research. Polyclonal rabbit 
anti-rat/mouse Bcl-2 antibody (BosterTM, CHN, at a dilution 
ratio of 1:60) and polyclonal rabbit anti-rat/mouse Bax an-
tibody (BosterTM, CHN, at a dilution ratio of 1:40) were 
used as primary antibodies. Paraffin-embedded tumor tissue 
sections were used for Bcl-2/Bax staining. The deparaf-
finized and rehydrated sections were treated through mi-
crowave irradiation twice at 550 W with 10 mmol/L citrate 
buffer (pH 6) for 3 min. After blocking with 4% normal 
goat serum, the sections were incubated for 1 h at room 
temperature with polyclonal rabbit anti-rat/mouse Bcl-2 
antibody at a dilution ratio of 1:60 in PBS (or with polyclo-
nal rabbit anti-rat/mouse Bax antibody at a dilution of 1:40 in 
PBS) as primary antibodies, then with goat-biotinylated an-
ti-mouse IgG, and finally with avidin-biotin complex con-
taining horseradish peroxides [18]. Immunostaining was 
detected with diaminobenzidine, and the slips of the tissues 
were counterstained with hematoxylin [19]. All slips were 
photographed using an inverted fluorescence microscope 
(TE-2000U, Nikon, Japan). 
2  Results  
2.1  Conjugation of 5-Fu to DASNP 
5-Fu has an imine group that can be used for conjugation to 
DASNP. The concentration of 5-Fu in 5-Fu-DASNP was 
10%±2%, as detected by a UV spectrophotometer. The 
SEM image showed that the drug loading nanoparticles 
were uniform in size, between 100 and 120 nm, and well 
dispersed (Figure 1). Compared with the starch curve, a 
peak of 1735 cm−1 appeared in the curve of DASNP, which 
is the band most characteristic of C=O vibrations in alde-
hyde groups. In the 5-Fu-DASNP curve, an acute-peak of 
2931/2890 cm−1 was replaced with the 2925 cm−1 peak, and  
 
Figure 1  SEM images of DASNP (a) and 5-Fu-DASNP (b).  
the 1732 and 779 cm−1 peaks disappeared. However, the 
3253 (NH), 1687 (CON), 1248 (CN), and 1155 
cm−1 (CF) peaks appeared in the 5-Fu-DASNP IR spec-
trum (Figure 2). In the 1H NMR spectrum, resonance peaks 
of chemical displacements δ=6.0×106 (CHN) and 
δ=7.4×106 (CHO) appeared. These results indicate that 
the conjugation of 5-Fu to DASNP was achieved. In the 
DASNP curve, the 2931/2890 cm−1 double peaks and the 
1732 cm−1 peak are characteristic peaks of C=O in –CHO, 
whereas the 779 cm−1 peak is the characteristic peak of C–H 
in –CHO. In the 5-Fu-DASNP curve, the 3253 (–N–H), 
1687 (–CO–N–), 1248 (–C–N–), and 1155 cm−1 (–C–F) 
peaks are apparent. 
 
 
Figure 2  IR spectrogram of the nanoparticles. 
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2.2  Release behavior of 5-Fu from 5-Fu-DASNP 
Figure 3 shows the release profiles of 5-Fu from 5-Fu- 
DASNP in aqueous solution of different pH values. The free 
5-Fu had a large burst release in PBS (pH 7.4). Its short 
release duration is attributed to the drug release that oc-
curred with a simple diffusion process through a dialysis 
bag (M.W. cutoff: 10000, Spectra/Por). 5-Fu release from 
the nanoparticles was slower in acid solution than in alka-
line solution. The half-releasing time t1/2 was 40 h at pH 3, 
24 h at pH 5, 16 h at pH 7, and 7 h at pH 9. These findings 
indicate that in faint acid solution, the release of 5-Fu- 
DASNP is slow and sustained. The sustained release effect 
under acidic conditions may be ascribed to DAS, which 
does not dissolve in acidic solution [20], and to the drug 
which is released with slow degradation of DASNP. How-
ever, DASNP can be dissolved and degraded under alkaline 
conditions [19]. Thus, no sustaining release effect in the 
alkaline solution was observed. 
2.3  Tumor cellular cytotoxicity assays (MTT assays) in 
vitro  
5-Fu, DASNP, 5-Fu/DASNP, and 5-Fu-DASNP were incu-
bated with MCF-7 cells in a medium for 48 h before the 
measurement of cell inhibiting rate through MTT assay. The 
cytotoxicity of the single DASNP was slight (Figure 4), and 
a high 5-Fu-DASNP inhibiting ratio was observed at low 
concentrations (100, 200, and 500 µg/mL), and a significant 
difference in inhibition effect was observed between the 
5-Fu-DASNP group and the 5-Fu/DASNP group (Figure 5). 
These findings demonstrate that the sustained release effect 
of 5-Fu-DASNP is obvious in vitro. However, under high  
 
 
Figure 3  Release rate of 5-Fu-DAS in different pH solutions.   
 
Figure 4  Cellular cytotoxicity assay of DASNP.  
concentrations (1000 µg/mL), the difference between 5-Fu/ 
DASNP and 5-Fu-DASNP disappeared. Saline was used as 
the control in this experiment. 
2.4  Efficacy and toxicity studies using human breast 
cancer MCF-7 in vivo 
To assess the antitumor activity in vivo, nanoparticles con-
taining 5-Fu were directly injected into the surrounding tis-
sues of the subcutaneously implanted solid tumor in mice, 
and the size of the tumor monitored using a digital caliper. 
At the end of the experiment, the mice were sacrificed, the 
solid tumors were obtained, and the inhibiting ratio was 
calculated. The curves of the tumor volume (Figure 6(a)) 
showed that the tumor growth trend is controlled by 5-Fu 
and 5-Fu-DASNP. Compared with saline and DASNP, the 
controlling effect of 5-Fu-DASNP was the best. The inhibi- 
ting ratio was monitored through the final tumor weight, 
which indicates that 5-Fu-DASNP exhibits obvious effects 
on the inhibition of tumor growth (Figure 6(b)). 5-Fu exhi- 
bited this inhibiting function, but it was weaker than that of 
5-Fu-DASNP, whereas a single-shot of DASNP showed 
very limited effect on antitumor activity (Figure 7).  
2.5  Immunohistochemistry assay 
The tumors were evaluated through hematoxylin and eosin 
stainings marked with karyon of cells with smalt color. To 
assess the impact of drug-loading nanoparticles on tumor 
cell viability, the solid tumors were sliced and the slips were 
stained with hematoxylin and eosin 72 h after treatment. 
They were then examined at low magnification (×100). Ob-
vious blanks in the tumor slips of the 5-Fu-DASNP and 
5-Fu groups were discovered (Figure 8, upper images), in-
dicating tumor cell death. However, the activity of the 
5-Fu-DASNP group was more remarkable than that of the 
free drug group. No indication of dead cells was observed in 
the saline and DASNP groups. 
Immunohistochemical studies of Bcl-2 and Bax were per-
formed. the results showed significant variant expressions 
 
 
Figure 5  Anti-tumor activities of NPs in vitro. Equivalent concentration 
of 5-Fu was 10 µg/mL, 20 µg/mL, 50 µg/mL, 100 µg/mL. * P<0.01, n=3;  
# P>0.05, n=3. 
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Figure 6  Trend of tumor inhibition in vivo. (a) Tumor growth trend curves; (b) solid tumor images. 
 
Figure 7  Drug-reduced efficacy for tumor. Tumor weight inhibiting rate, 
mean+SEM, n=6. * P<0.05, n=6. 
between Bcl-2 and Bax in each experiment group (Figure 8, 
middle and lower images). In the tumor tissue treated with 
saline, many brown blocks appeared in Bcl-2 staining (Fig-
ure 8, middle images), but none was found in Bax staining 
(Figure 8, lower images). This finding indicates high ex-
pression of Bcl-2 in the cytoplasm of the tumor cells and 
near absence of Bax expression, as well as the absence of 
apoptosis in the saline group. However, Bcl-2 was faint and 
Bax was visible in the tumor tissues treated with 5-Fu and 
5-Fu-DASNP. The 5-Fu-DASNP expression was most 
prominent. In the 5-Fu-DASNP group, the Bcl-2 expression 
was very weak, whereas that of Bax was very strong. These 
results indicate that drug-loading nanoparticles greatly in-
duce the apoptosis of the tumor tissue cells in vivo. 
3  Discussion  
Sodium periodate can oxidize starch, specifically yielding 
2,3-dialdehyde starch. Drug-loading is low when aldehyde 
content is very low; if the content is very high, the formation 
of particle drug carriers is difficult [6,20]. Thus, dialdehyde 
starch nanoparticle with about 40% of the aldehyde 
 
 
Figure 8  H&E staining and Bcl-2/Bax immunohistochemistry studies of tumors in the saline group, DASNP without drug, 5-Fu, and 5-Fu-DASNP. Upper 
images are H&E staining of representative specimens at ×100 magnification. Middle images are Bcl-2 staining for each group at ×150 magnification. Lower 
images are Bax staining for each group at ×150 magnification. The blown yields of Bcl-2 and Bax staining are highlighted in the images (middle and lower). 
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group was used, the mass ratio of starch-to-sodium-perio- 
date was controlled, and the reaction time was determined 
[21]. The cellular cytotoxicity of topical DASNP was simi-
lar to starch (Figure 4). Hence, it can be used as a safe drug 
carrier. 
Some protocols have been implemented to improve the 
curative effect of 5-Fu in tumor therapy, such as preparing 
prodrugs [22,23] and loading them to polymers [24–26]. 
However, most of the polymer carriers are physical loading 
drugs, and the stability of their drug complexes is poor. The 
chemical activity of DASNP is due to the two aldehyde 
groups in each glucose monomer, which can conjugate with 
the imine groups in 5-Fu. The drug release profile (Figure 3) 
shows that the 5-Fu complex became stable with the sus-
tained release of 5-Fu. An abrupt release occurred during 
the first one hour of the release profile, which indicates the 
release of nonspecific physically adsorbed 5-Fu.  
Previous studies have indicated that DAS and its deriva-
tives have potential biological activities, such as antineo-
plastic, antiviral, and anti-inflammatory activities [27]. In 
the present research, DASNP exhibited tumor growth-  
inhibitory effects on human breast cancer in vitro and in 
vivo (Figure 7). The flow cytometry results showed that the 
cell cycle phases of the Mcf-7 cells were altered (Figure 9). 
A significant increase in G0/G1 population and a remarkable 
reduction in S population were induced in Mcf-7 cells 
treated with DASNP, compared with the control group. 
Hence, topical DASNP has some antineoplastic activity 
through G0/G1 phase blockage. Further study is needed to 
thoroughly ascertain the mechanism behind it.  
The 5-Fu-DASNP complex had significant antitumor ef-
fect in vivo. At least three reasons are therefore apparent:  
(1) the classical therapeutic impact of 5-Fu on human breast 
cancer through G0/G1 phase blockage [28]; (2) the potential 
antineoplastic activity of the DASNP carrier material; and 
(3) the sustained release function of the 5-Fu complex. 
In summary, DASNP is a potential new drug carrier for 




Figure 9  The influences of nanoparticles in every phase of cell cycle in 
human breast cancer.  
DASNP for 5-Fu likely contributes to its pronounced anti-
tumor activity. This feature may be useful in similar treat-
ments in humans. Hence, DASNP as a non-toxic carrier of 
antitumor drugs must be further explored. 
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